BTIG Research Forecasts Strong Price Appreciation for Maze Therapeutics (NASDAQ:MAZE) Stock

Maze Therapeutics (NASDAQ:MAZE) had its price objective hoisted by BTIG Research from $30.00 to $37.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 58.80% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. HC Wainwright initiated coverage on Maze Therapeutics in a report on Wednesday, July 23rd. They set a “buy” rating and a $34.00 target price for the company. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Finally, Wedbush initiated coverage on Maze Therapeutics in a report on Tuesday, July 8th. They issued an “outperform” rating and a $17.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $30.17.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $23.30 on Friday. The business has a 50 day simple moving average of $15.28 and a two-hundred day simple moving average of $12.28. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $25.50.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.02.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds have recently modified their holdings of the business. TRV GP IV LLC purchased a new position in Maze Therapeutics during the 1st quarter valued at about $66,874,000. Frazier Life Sciences Management L.P. boosted its holdings in Maze Therapeutics by 10.6% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the period. ARCH Venture Management LLC purchased a new position in Maze Therapeutics during the 1st quarter valued at about $45,362,000. Matrix Capital Management Company LP purchased a new position in Maze Therapeutics during the 1st quarter valued at about $27,373,000. Finally, Alphabet Inc. purchased a new position in Maze Therapeutics during the 1st quarter valued at about $26,561,000.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.